# Sharps Technology signs $200M syringe sales agreement with Nephron Pharmaceuticals

Sharps Technology Inc. signed a 5-year, $200 million syringe sales agreement with Nephron Pharmaceuticals, complementing its asset purchase agreement to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. Product delivery is scheduled to begin in Q2 2025.

- Type: Contract
- Announced: 2024-05-30
- Where: West Columbia, South Carolina, United States
- Value: $200.0M
- Status: announced
- Products: prefillable specialty copolymer syringes
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Sharps Technology](https://endata.com/companies/11050.md)
- [Nephron Pharmaceuticals](https://endata.com/companies/11051.md) (customer)

## Sources

- [biospace.com](https://www.biospace.com/sharps-technology-signs-5-year-200-million-syringe-sales-agreement-and-amendment-to-asset-purchase-agreement-to-begin-producing-prefillable-specialty-copolymer-syringes-in-the-u-s), 2024-05-30: "Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.